July 14, 2014

Stanton A. Glantz, PhD

FDA Should Clarify that Tobacco Products with Inadequate SE Applications Must be Removed from the Market

We just submitted this public comment to FDA on the FDA's proposed guideline tightening up the process for evaluating substantial equivalence claims.  (The proposed guideline is available here.)  While we think that this is a step in the right direction, we think that the FDA needs to be more explicit about how it is handling inadequate applications.  (This is different from deeming.)
 
FDA Should Clarify that Tobacco Products for which FDA has not Received Adequate SE Reports by Established Deadlines Must be Removed from the Market
 
FDA-2014-D-0800
 
 
Lauren Lempert, JD MPH
Stanton Glantz, PhD
University of California San Francisco\
 
July 14, 2014
 
            FDA’s Draft Guidance on Substantial Equivalence Reports: Manufacturer Requests for Extensions or to Change the Predicate Tobacco Product is a good step in the right direction.  FDA correctly states that manufacturers have had more than enough time to prepare SE reports and amend pending SE reports to address any deficiencies within the time period granted in the deficiency letters.  However, FDA should clarify the consequences to manufacturers whose SE reports for “provisional tobacco products” (those that were first marketed in the U.S. between February 15, 2007 and March 22, 2011, and for which SE reports were submitted no later than March 22, 2011, and that remain on the market until FDA issues a determination that they are not substantially equivalent and orders them off the market) are deficient. 
 
Our reading of the Draft Guidance is that FDA’s intention is to deny marketing approval to tobacco products for which inadequate SE reports have been submitted, and therefore neither “provisional tobacco products” nor “non-provisional tobacco products” may remain on the market.  However, while FDA clearly articulates this consequence for inadequate non-provisional reports and requests to change the predicate product, the consequence for inadequate SE reports for provisional tobacco products for which FDA does not grant an extension of time is ambiguous.
 
To date, 3,513 tobacco products remain on the market for which provisional SE applications were submitted, but which FDA has neither approved nor denied.   http://www.accessdata.fda.gov/FDATrack/track?program=ctp&id=CTP-OS-total-product-submissions-received&fy=all; http://tobacco.ucsf.edu/fda-removes-first-4-tobacco-products-market-3513-go.  FDA should act quickly to determine whether these products are “substantially equivalent” to valid predicate products on the market and do not raise different questions of public health.  FDA’s Draft Guidance announces that CTP plans to grant extensions of time to respond to deficiency letters “in very limited instances.”  FDA should state explicitly that provisional tobacco products must be immediately removed from the market if manufacturers did not address SE report deficiencies within the specified time period and FDA did not grant an extension of time.    
 
On April 18, 2014, FDA announced the establishment of performance measures and timeframes for the review of certain tobacco products, including non-provisional or “regular” SE reports. http://www.fda.gov/TobaccoProducts/NewsEvents/ucm393894.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery   FDA established a timeframe to review and act on an original SE report within 90 days of FDA receipt, and to review and act on a SE report resubmission within 90 days of receipt.  It noted that as of March 24, 2014, there was no longer a backlog of regular SE reports awaiting scientific review, and that as of April 4, 2014, FDA had concluded the review process for 232 of the 981 regular (non-provisional) reports that had been received before March 31, 2014.  Since 87 days have passed since this announcement, presumably FDA has acted on many more non-provisional reports.  FDA should set similar timeframes for review of the 3,513 provisional tobacco products that remain on the market, and not allow manufacturers to delay the process with unnecessary requests for extensions of time or requests to change the predicate tobacco product. 
 
Our comment has tracking number 1jy-8d8l-vhtp.
 
If you want to submit a comment, click here.

Comments

Comment: 

The most rationale approach by FDA to deal with the backlog of 3,600 SE applications and failure of the industry to submit New Product applications is to choose the top 300 selling products (94% of the market) based on Neilson market share data and separate out those that have applied for an SE and those that haven’t. To date, with the exception of Newport Gold, all denials and approvals have to date been for niche products with deminimus market share and in reality no or extremely limited public health impact.
 
Of those that have filed an SE report, FDA should identify the predicate and then measure growth in sales over the past three to five years between the SE and its predicate. This is a crude measure but the most reflective of the Law’s legal standard of public health impact.
 
For those SEs that have had market growth greater than the predicate they should be considered only to raise “new questions of the public health”, denied and required to file for an NTP.  This is a deminimus onus based on a crude measure but is far more rationale that the three thousand plus and countless hours spent authorizing Newport Gold.
 
This approach was taken by Massachusetts in testing for nicotine and smoke toxins and did not require 250 staffers and $850 million dollars and it worked for reporting purpose that were meaningful . During negotiations the companies agreed to a similar scheme for testing human exposure to tobacco products once PM had completed its Total Human Exposure study which it did in 2007.   
 
The Newport Gold reports are all based on  crude assessments of relative toxic differences between the SE and predicate based on machine testing which Volume 13 of the NCI Monograph rejected as way to assess public health impact.
 
Clinical trials were called for in the final guidance which could have assessed topography, abuse potential such as attractiveness to youth and  deterrence to quitting between the SE and predicate but never were submitted to FDA which approved the product regardless. 
 
The decision ignored the violation of other guidance that if the pack name was changed from light to an associated color (gold) which raised “new  questions of the public health” then a NTP application was required.  
 
One has to wade through thousands of pages of materials on Newport Gold to realize that some is wrong in the State of DC.
This is not how social democracies work.
 
Greg Connolly DDS
Harvard School of Public Health

Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.